Ding X, Zhang H, Chen J, Yang M, Huang Z, Lei Y
Mol Med. 2025; 31(1):78.
PMID: 40000966
PMC: 11863856.
DOI: 10.1186/s10020-025-01130-8.
Zhang Y, Xie S, Li W, Gu J, Zhang X, Ni B
MedComm (2020). 2025; 6(3):e70108.
PMID: 39974663
PMC: 11836349.
DOI: 10.1002/mco2.70108.
Somala C, Sathyapriya S, Bharathkumar N, Anand T, Mathangi D, Saravanan K
Protein J. 2025; 44(1):21-34.
PMID: 39923206
DOI: 10.1007/s10930-025-10250-3.
Liu L, Qiu Y, Suo Y, Tong S, Wang Y, Zhang X
Acta Pharm Sin B. 2025; 14(12):5382-5392.
PMID: 39807332
PMC: 11725161.
DOI: 10.1016/j.apsb.2024.07.016.
Tian S, Song Y, Guo L, Zhao H, Bai M, Miao M
J Cell Mol Med. 2025; 29(1):e70344.
PMID: 39779466
PMC: 11710941.
DOI: 10.1111/jcmm.70344.
N6-methyladenosine RNA methylation, a new hallmark of metabolic reprogramming in the immune microenvironment.
Li X, Peng L, Yang X, Luo J, Wang J, Mou K
Front Immunol. 2025; 15:1464042.
PMID: 39759516
PMC: 11695279.
DOI: 10.3389/fimmu.2024.1464042.
FTO in health and disease.
Benak D, Sevcikova A, Holzerova K, Hlavackova M
Front Cell Dev Biol. 2025; 12:1500394.
PMID: 39744011
PMC: 11688314.
DOI: 10.3389/fcell.2024.1500394.
Epitranscriptomic RNA mA Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities.
Uddin M, Wang Z, Yang C
Adv Sci (Weinh). 2024; :e2403936.
PMID: 39661414
PMC: 11775542.
DOI: 10.1002/advs.202403936.
Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity.
Cui Y, Wei J, Fan H, Li W, Zhao L, Wilkinson E
Proc Natl Acad Sci U S A. 2024; 121(51):e2407910121.
PMID: 39661064
PMC: 11665913.
DOI: 10.1073/pnas.2407910121.
Regulation and application of mA modification in tumor immunity.
Xiong Q, Zhang Y, Zheng Y, Zhu Q
Sci China Life Sci. 2024; .
PMID: 39648245
DOI: 10.1007/s11427-024-2648-0.
Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects.
Kaur P, Sharma P, Bhatia P, Singh M
Front Oncol. 2024; 14:1445794.
PMID: 39600630
PMC: 11590065.
DOI: 10.3389/fonc.2024.1445794.
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S
Signal Transduct Target Ther. 2024; 9(1):332.
PMID: 39592582
PMC: 11627502.
DOI: 10.1038/s41392-024-02039-0.
Trends and frontiers of RNA methylation in cancer over the past 10 years: a bibliometric and visual analysis.
Liu B, Gao X, Piao Y
Front Genet. 2024; 15:1461386.
PMID: 39473440
PMC: 11519982.
DOI: 10.3389/fgene.2024.1461386.
Clinician's Guide to Epitranscriptomics: An Example of N-Methyladenosine (mA) RNA Modification and Cancer.
Kvolik Pavic A, conkas J, Mumlek I, Zubcic V, Ozretic P
Life (Basel). 2024; 14(10).
PMID: 39459530
PMC: 11508930.
DOI: 10.3390/life14101230.
Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.
Tang L, Tian H, Min Q, You H, Yin M, Yang L
Cell Commun Signal. 2024; 22(1):513.
PMID: 39434167
PMC: 11492518.
DOI: 10.1186/s12964-024-01854-w.
Role of N6-methyladenosine methylation in head and neck cancer and its regulation of innate immune pathways.
Cao L, Huang G, Fan J, Liu X, Ma Z
Front Immunol. 2024; 15:1458884.
PMID: 39403369
PMC: 11471572.
DOI: 10.3389/fimmu.2024.1458884.
Fat Mass- and Obesity-Associated Protein (FTO) Promotes the Proliferation of Goat Skeletal Muscle Satellite Cells by Stabilizing DAG1 mRNA in an IGF2BP1-Related mA Manner.
Yao J, Xu L, Zhao Z, Dai D, Zhan S, Cao J
Int J Mol Sci. 2024; 25(18).
PMID: 39337293
PMC: 11432635.
DOI: 10.3390/ijms25189804.
Writers, readers, and erasers RNA modifications and drug resistance in cancer.
Chen D, Gu X, Nurzat Y, Xu L, Li X, Wu L
Mol Cancer. 2024; 23(1):178.
PMID: 39215288
PMC: 11363509.
DOI: 10.1186/s12943-024-02089-6.
Inhibitor of FTO, Rhein, Restrains the Differentiation of Myoblasts and Delays Skeletal Muscle Regeneration.
Li R, Cao Y, Wu W, Liu H, Xu S
Animals (Basel). 2024; 14(16).
PMID: 39199967
PMC: 11350746.
DOI: 10.3390/ani14162434.
Insights into the mA demethylases FTO and ALKBH5 : structural, biological function, and inhibitor development.
Gao Z, Zha X, Li M, Xia X, Wang S
Cell Biosci. 2024; 14(1):108.
PMID: 39192357
PMC: 11351023.
DOI: 10.1186/s13578-024-01286-6.